Table 1.

Patient demographics and clinical status, cancer and CIN/FN history, and management

	Under	Correct	Over	p
	251 (17.4%)	817 (56.6%)	376 (26.0%)
Demographics and clinical status
Gender				n.s.
Male	45.0%	37.2%	37.8%
Female	55.0%	62.8%	62.2%
Age (M ± SD, Mdn)	65.2 ± 11.0, 67	61.8 ± 12.5, 63	57.7 ± 9.5, 58	<0.001
ECOG performance status
0	31.5%	40.7%	47.4%
1	57.8%	46.1%	46.5%
2	9.9%	10.9%	4.2%	0.011
3	0.9%	2.4%	1.7%
4	0.0%	0.0%	0.3%
History of repeated infections	4.3%	2.3%	2.0%	n.s.
FN risk factors (EORTC)
High risk
Age ≥ 65 years	61.4%	46.1%	17.3%	<0.001
Increased risk
Advanced diseasea	15.3%	11.2%	18.2%	0.009
History of FN	6.5%	0.8%	1.8%	0.029
No antibiotic prophylaxis	90.0%	85.4%	91.6%	n.s.
Other factors
Poor performance and/or nutritional status	11.8%	16.2%	8.5%	0.005
Female gender	55.0%	62.8%	62.2%	n.s.
Hemoglobin <12 g/dL	60.0%	34.4%	39.4%	<0.001
Renal, cardiovascular, or liver disease	31.6%	24.7%	13.5%	<0.001
Patient risk score (M ± SD, Mdn)	3.8 ± 2.0, 4	2.9 ± 2.0, 3	2.0 ± 1.6, 1.5	<0.001
Cancer
Tumor type				0.009
Solid	72.5%	73.7%	88.0%
Hematological	27.5%	26.3%	12.0%
Prior treatments
Chemotherapy	37.1%	26.9%	39.1%	0.004
Of these adjuvant in metastatic setting	41.8%	48.2%	50.4%	n.s.
Of these prior lines of chemo	48.1%	47.7%	56.1%	n.s.
1	42.1%	48.9%	60.3%
2	31.6%	27.3%	24.7%	n.s.
≥3	26.3%	23.9%	15.1%
Radiation therapy	19.5%	16.9%	23.1%	n.s.
Chemotoxicity				<0.001
<10%	0.0%	2.1%	36.4%
10–20%	46.6%	36.0%	63.6%
≥20%	53.4%	61.9%	0.0%

^aStage 4 (stage 3 if multiple myeloma) and prior chemotherapy in metastatic setting n.s. not significant